CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer

Abstract

BACKGROUND:

CA125 level normalization at different chemotherapy cycles has been reported to be a prognosticator in advanced epithelial ovarian cancer.

OBJECTIVE:

In the present study, we investigated whether the time (in days) to CA125 normalization or nadir during treatment could be used as markers to predict survival.

METHODS:

Patients with FIGO stage III–IV epithelial ovarian cancer treated with cytoreductive surgery followed by adjuvant chemotherapy between 2008 and 2016 were enrolled in this retrospective study. Clinicopathological characteristics, changes in CA125 level during treatment, and survival outcomes were analyzed. Time-dependent receiver operating characteristic curve analysis was used to determine the optimal cut-off values of the time to normalization and time to nadir of CA125 levels to predict survival. Univariate and multivariate Cox regression analysis were used to examine the impact of each variable on survival.

RESULTS:

A total of 106 patients were included in the analysis. The optimal cut-off values for the time to normalization and nadir for predicting survival were 60 and 194 days, respectively. In Kaplan-Meier survival analysis, CA125 level normalization $\leqslant$ 60 days and CA125 $\leqslant$ 35 u/mL after the third cycle, and CA125 level $\leqslant$ 10 u/mL after the sixth cycle of chemotherapy were associated with significantly better 5-year progression-free survival (PFS) and overall survival (OS). In multivariate analysis, only CA125 level normalization $>$ 60 days was significantly associated with poor survival outcomes (PFS, HR 2.62 [95% CI: 1.54, 4.45], $p=$ 0.004; OS, HR 2.40 [95% CI: 1.19, 4.81], $p=$ 0.014).

CONCLUSIONS:

Normalization of CA125 level within 60 days after cytoreductive surgery followed by adjuvant chemotherapy in patients with advanced ovarian epithelial cancer could be used as a marker to predict survival.

Keywords

Epithelial ovarian cancer advanced ovarian cancer carbohydrate antigen 125 normalization survival outcome

1. Introduction

The serum level of cancer antigen 125 (CA125) [1] is a widely used biomarker for the diagnosis [2], evaluation of therapeutic response [3, 4, 5, 6, 7, 8], and detection of the recurrence of epithelial ovarian cancer (EOC) [9, 10, 11]. All histologic types of EOC, including the most common serous cell subtype, mucinous tumors, and clear cell tumors are associated with elevated CA125 levels before treatment [12, 13]. Around 75% of patients diagnosed with EOC have advanced stage disease (International Federation of Gynecology and Obstetrics [FIGO] IIb-IV) with a 5-year survival rate of around 29% [2, 14]. The standard treatment approach for advanced stage EOC includes cytoreductive surgery (CRS) and postoperative adjuvant chemotherapy [15] or neoadjuvant chemotherapy (NACT) followed by interval CRS [16, 17, 18].

Previous studies have extensively explored the use of CA125 level in predicting survival outcomes in patients with advanced EOC, including single values (e.g., pretreatment, time to nadir, or time to normalization) [19, 20, 21] and kinetic parameters such as percentage decrease and half-life of CA125 during chemotherapy [5, 6]. Most of these studies have reported that normalization of CA125 level at the first, second, or third chemotherapy cycle is a good prognosticator. However, previous studies have shown a wide range of timing of chemotherapy initiation from as fast as 1 week to a delay of more than 6 weeks after CRS [22]. Therefore, CA125 normalization at the third cycle may represent a wide range of times depending on the study. No previous study has investigated the best cut-off day of the time (in days) required for CA125 reaching normal or nadir to predict survival in advanced EOC. Furthermore, differences in the statistical methods used and inconsistent results in the previous studies highlight the need for an accurate and reliable marker to predict the prognosis of EOC before and during treatment [4, 11, 23, 24]. Therefore, the aim of this study was to determine whether the time to CA125 level normalization ( $<$ 35 u/mL) or reaching a nadir the day after primary CRS and during adjuvant chemotherapy could be used as a surrogate marker to predict progression-free survival (PFS) and overall survival (OS) in patients with advanced EOC.

2. Materials and methods

2.1 Study population

In this retrospective study, we retrieved the medical records of patients with FIGO stage III–IV EOC treated with primary CRS followed by adjuvant chemotherapy between January 2008 and December 2016 at Kaohsiung Chang Gung Memorial Hospital. The inclusion criteria were: 1. all histological types of EOC; 2. advanced ovarian cancer disease defined as FIGO stage III–IV; 3. patients who underwent six or more cycles of platinum-based adjuvant chemotherapy after primary CRS; 4. patients who had serial CA125 values before and during every cycle of adjuvant chemotherapy; and 5. patients who underwent clinical and imaging studies during follow-up or when being evaluated for recurrence. The exclusion criteria were: 1. patients with a normal CA125 level ( $\leqslant$ 35 u/mL) before treatment and those with missing CA125 data before surgery and during adjuvant chemotherapy; and 2. patients who received NACT. The Institutional Review Board of Chang Gung Memorial Hospital approved this study (201901805BO).

2.2 Data collection and definition

The following clinical data were retrieved from the medical records of our hospital: age of the patient, pathologic characteristics of the tumor (histologic type and grade), FIGO stage at primary diagnosis, preoperative level of CA125, and CA125 levels after the first, second, third, and sixth cycle of adjuvant chemotherapy. A normal CA125 level was defined as $\leqslant$ 35 u/mL.

Data of the primary surgery were based on operative records documented by the surgeon. A residual tumor $<$ 1 cm after CRS was defined as optimal CRS, whereas a residual mass of $\geqslant$ 1 cm was defined as suboptimal CRS [24].

The treatment date was defined as the date of undergoing primary CRS. Preoperative serum CA125 values were measured within 2 weeks before the treatment date, and usually 1 day before the CRS. The time to normalization/nadir of CA125 level (in days) was calculated from the treatment date until the date that a normal/nadir CA125 level was documented. During adjuvant chemotherapy, CA125 levels were measured prior to each chemotherapy cycle, which was around 1–3 days before starting chemotherapy. The date of last follow-up was defined as the last medical record of a patient visit to either the gynecologic clinic or any other medical department in our hospital.

To evaluate disease-related outcomes, disease progression was defined as newly developed lesions confirmed by imaging studies following the detection of elevated CA125 levels. PFS and OS were presented in months, and calculated from the treatment date to the date of disease progression or death due to any cause, respectively.

Figure 1.

Flowchart describing the study population selection.

2.3 Statistical analysis

Univariate and multivariate Cox regression analyses were used to investigate the effects of each clinicopathological factor and CA125-related factor on survival. The CA125-related variables (preoperative CA125 level, CA125 levels after the first, second, third and sixth chemotherapy cycles, time to normalization, and time to nadir) were determined after completing a literatures review. The cut-off CA125 values we used after the first (35 u/mL), second (35 u/mL), third (35 u/mL), and sixth (10 u/mL) chemotherapy cycles were based on the results of earlier studies which showed statistical significance in terms of PFS and OS [3, 6, 7, 9, 25, 26, 27, 28, 29, 30]. We used time-dependent receiver operating characteristic (ROC) curve analysis to identify the optimal cut-off value of preoperative CA125 level, and the optimal cut-off value (in days) for the time to CA125 normalization and time to nadir of CA125 in predicting survival. Univariate Cox regression analysis was performed first with each clinicopathological factor and CA125-related factor, and statistically significant variables were identified. The variables reaching statistical significance were then entered into multivariate Cox proportional hazards analysis to identify the most significant independent prognostic factors for PFS and OS. Actuarial rates of survival were estimated using the Kaplan-Meier method, and statistical differences between groups were examined using the log rank test. All statistical analyses were performed using MedCalc and SPSS software (SPSS Inc., Chicago, IL, USA). All $p$ values were two-sided, and $p<$ 0.05 was considered to indicate statistical significance.

3. Results

3.1 Patient characteristics

A total of 106 patients met the inclusion criteria and were included in this retrospective study. The process of patient selection is shown in Fig. 1. The patients’ characteristics and CA125-related variables are presented in Table 1. The median age of the patients was 53 years (range 37–81 years). Most patients (65%) had FIGO stage IIIC disease at primary diagnosis, and the most common tumor histology was the serous type (61.3%), followed by the endometrioid type (15.0%). Fifty-three (50%) patients had grade 3 tumors. Eighty-five (80.2%) patients achieved optimal debulking after primary CRS, and the other 21 patients (19.8%) had residual tumors $>$ 1 cm after CRS. Most patients (74.5%) received six cycles of adjuvant chemotherapy, and a taxane-platinum combination was the most commonly used chemotherapy regimen. The mean time between primary CRS and first cycle of adjuvant chemotherapy was 20.2 days.

Table 1
Characteristics of the study population

Variable	Patients included, $n=$ 106 (%)
Age (years)
Median 53
$\leqslant$ 50	43 (40.6)
$>$ 50	63 (60.4)
Histology
Serous	65 (61.3)
Mucinous	10 (9.5)
Clear cell	13 (12.3)
Endometrioid	16 (15.0)
Others	2 (1.9)
Tumor grade
1	9 (8.5)
2	42 (39.6)
3	53 (50.0)
Unknown	2 (1.9)
FIGO stage
III	94 (88.7)
IV	12 (11.3)
Residual tumor status after primary CRS
Optimal debulking ( $<$ 1 cm)	85 (80.2)
Suboptimal debulking ( $\geqslant$ 1 cm)	21 (19.8)
No. of chemotherapy cycles
6	79 (74.5)
$>$ 6	27 (25.5)
Pre-operative CA125 level (u/mL)
Median	651.2
$\leqslant$ 430	45 (42.5)
$>$ 430	61 (57.5)
After 1 ${}^{\text{st}}$ CTx CA125 level (u/mL)
Median	40.35
$\leqslant$ 35	50 (47.1)
$>$ 35	56 (52.9)
After 2 ${}^{\text{nd}}$ CTx CA125 level (u/mL)
Median	16.3
$\leqslant$ 35	77 (72.6)
$>$ 35	29 (27.4)
After 3 ${}^{\text{rd}}$ CTx CA125 level (u/mL)
Median	13.6
$\leqslant$ 35	86 (81.1)
$>$ 35	20 (18.9)
After 6 ${}^{\text{th}}$ CTx CA125 level (u/mL)
Median	11
$\leqslant$ 10	43 (40.6)
$>$ 10	63 (59.4)
Time to nadir (days)
Mean	140
$\leqslant$ 194	85 (80.2)
$>$ 194	21 (19.8)
Time to normalization (days)
Mean	56
$\leqslant$ 60	59 (55.7)
$>$ 60	47 (44.3)

CTx, chemotherapy; CA125, cancer antigen 125; CRS, cytoreductive surgery; FIGO, International Federation of Gynecology and Obstetrics.

3.2 Distribution of CA125-related prognostic factors

We used time-dependent ROC curve analysis to define the optimal cut-off values of preoperative CA125 level and time to nadir and time to normalization of CA125 level in predicting survival. The optimal cut-off values and areas under the curve (AUCs) were as follows: pre-operative CA125 level: 430 u/mL (AUC: 0.521); time to nadir: 194 days (AUC: 0.556); time to normalization: 60 days (AUC: 0.737) (Figure-supplement). The mean preoperative CA125 level was 1875 u/mL, and 45 (42.5%) patients had a preoperative CA125 level $\leqslant$ 430 u/mL. The median CA125 levels after the first, second, third, and sixth cycle of adjuvant chemotherapy were 651.2 u/mL, 40.4 u/mL, 16.3 u/mL, and 11.0 u/mL, respectively. The mean time to CA125 nadir was 140 days, and the mean time to CA125 normalization was 56 days (Table 1).

3.3 Impact of CA125-related variables on survival

Univariate Cox regression analysis of clinicopathological and CA125-related factors were done, and each variate was divided into two subgroups to compare its impact on survival (Table 2). The results revealed that a CA125 level $>$ 35 u/mL after the first, second, and third cycles of adjuvant chemotherapy, CA125 level $>$ 10 u/mL after the sixth cycle of adjuvant chemotherapy, and time to normalization $>$ 60 days were significant poor prognostic factors for PFS. In addition, a CA125 level $>$ 35 u/mL after the third cycle of adjuvant chemotherapy, CA125 level $>$ 10 u/mL after the sixth cycle, and time to normalization $>$ 60 days were also significantly associated with poor OS. Accordingly, the CA125 level after the third and sixth cycles of adjuvant chemotherapy and time to CA125 normalization were selected as the most important prognostic factors for both PFS and OS. Age, histologic type, tumor grade, and residual tumor status were not statistically significant prognostic factors for either PFS or OS (Table 2).

Table 2
Univariate Cox regression analysis of clinicopathological characteristics, and CA125-related prognostic factors for progression-free survival (PFS) and overall survival (OS)

Variable	PFS		OS
	HR (95% CI)	$p$ value	HR (95% CI)	$p$ value
Age (years)
$\leqslant$ 50	1		1
$>$ 50	1.30 (0.59 to 2.76)	0.527	1.19 (0.62 to 2.29)	0.602
Histology
Non-serous	1		1
Serous	1.24 (0.74 to 2.06)	0.410	0.71 (0.36 to 1.40)	0.328
Tumor grade
1–2	1		1
3	1.27 (0.77 to 2.08)	0.346	1.17 (0.61 to 2.23)	0.636
Residual tumor status after primary CRS
Optimal	1		1
Suboptimal	1.64 (0.85 to 3.18)	0.142	1.43 (0.63 to 3.27)	0.393
Pre-operative CA125 level (u/mL)
$\leqslant$ 430	1		1
$>$ 430	1.43 (0.87 to 2.36)	0.159	1.50 (0.78 to 2.88)	0.219
After 1st CTx CA125 level (u/mL)
$\leqslant$ 35	1		1
$>$ 35	2.24 (1.36 to 3.70)	0.002	1.33 (0.69 to 2.53)	0.392
After 2nd CTx CA125 level (u/mL)
$\leqslant$ 35	1		1
$>$ 35	3.60 (1.78 to 7.10)	$<$ 0.001	2.17 (0.94 to 5.01)	0.071
After 3rd CTx CA125 level (u/mL)
$\leqslant$ 35	1		1
$>$ 35	7.81 (2.97 to 20.53)	$<$ 0.001	4.74 (1.62 to 13.81)	0.004
After 6th CTx CA125 level (u/mL)
$\leqslant$ 10	1		1
$>$ 10	1.77 (1.06 to 2.95)	0.028	2.53 (1.29 to 4.97)	$<$ 0.001
Time to nadir (days)
$\leqslant$ 194	1		1
$>$ 194	0.81 (0.44 to 1.49)	0.499	0.66 (0.29 to 1.48)	0.312
Time to normalization (days)
$\leqslant$ 60	1		1
$>$ 60	2.82 (1.65 to 4.82)	$<$ 0.001	2.88 (1.47 to 5.64)	0.002

CI, confidence interval; HR, hazard ratio; CTx, chemotherapy; CA125, cancer antigen 125; OS, overall survival; PFS, progression-free survival; CI, confidence interval; HR, hazard ratio.

In Kaplan-Meier survival analysis, a time to CA125 level normalization $\leqslant$ 60 days was associated with better 5-year PFS (53% vs. 20%, $p<$ 0.001) and OS (77% vs. 44%, $p=$ 0.002). In addition, CA125 normalization after the third cycle of adjuvant chemotherapy was associated with better 5-year PFS (45% vs. 10%, $p<$ 0.001) and OS (67% vs. 47%, $p=$ 0.004), and a CA125 level $\leqslant$ 10 u/mL after the sixth cycle of chemotherapy was also associated with better 5-year PFS (52% vs. 31%, $p<$ 0.001) and OS (79% vs. 54%, $p=$ 0.002) (Fig. 2A–C).

Figure 2.

Kaplan-Meier survival curves for progression-free survival and overall survival according to CA125 level after the third cycle of chemotherapy (2A), after the sixth cycle of chemotherapy (2B), and normalization within 60 days (2C).

To determine the most significant prognostic factors for OS and PFS, we performed multivariate Cox proportional hazards analysis with statistically significant variables in the univariate analysis and factors which have been reported to have clinical importance on survival outcomes in previous studies [13, 24, 25, 27, 29, 31], including CA125 values after the first, second, third and sixth cycle of chemotherapy, time to normalization (days), tumor grade and residual tumor size after debulking. The results of multivariate analysis showed that only CA125 normalization time $>$ 60 days was significantly associated with poor PFS and OS (PFS, HR $=$ 2.09 [95% CI: 1.18–3.70], $p=$ 0.0118; OS, HR $=$ 2.36 [95% CI: 1.10–5.05], $p=$ 0.027) (Table 3).

Table 3

Multivariate Cox regression analysis (backward method) of prognostic factors for progression-free survival (PFS) and overall survival (OS). Multivariate association was adjusted by CA125 after the first, second, third, sixth cycle of chemotherapy, time to normalization (days), tumor grade, and residual tumor size

Variable	PFS		OS
	HR (95% CI)	$p$ value	HR (95% CI)	$p$ value
Time to normalization (days)
$\leqslant$ 60	1		1
$>$ 60	2.62 (1.54 to 4.45)	0.004	2.40 (1.19 to 4.81)	0.014

OS, overall survival; PFS, progression-free survival; CI, confidence interval; HR, hazard ratio; CTx, chemotherapy; CA125, cancer antigen 125.

4. Discussion

In present study, we demonstrated that a time to normalization of CA125 level within 60 days was the strongest and only prognostic factor for better PFS and OS in patients with advanced EOC treated with primary CRS followed by adjuvant chemotherapy. To the best of our knowledge, only one similar study has been published, however the authors enrolled patients with all FIGO stages for analysis, including 52.6% with stage I–II. The authors reported that CA125 normalization within 1 month was significantly associated with survival, however a major concern is that they did not include stage or residual tumor status, both of which are considered to be universally important prognostic factors, in the final multivariate Cox regression analysis [25].

CA125 level normalization by the third cycle of chemotherapy [24, 26, 27] and CA125 level $\leqslant$ 10 u/mL after the sixth cycle of chemotherapy [9, 28] have been reported to be significant predictive factors for survival in previous studies, which is consistent with our univariate analysis results. Rocconi et al. [24] conducted a retrospective study of 262 patients with FIGO stage II–IV EOC with an elevated CA125 level at primary diagnosis, all of whom were treated with primary CRS followed by platinum-taxane-based adjuvant chemotherapy. The authors found that CA125 normalization by the third cycle of adjuvant chemotherapy, lower stage, and optimal debulking were associated with better survival outcomes after primary CRS. In the present study we focused on a more unique population of FIGO stage III–IV EOC patients, and found that debulking status was not associated with survival. We excluded patients who underwent NACT followed by interval CRS, so only 20% of our patients had a suboptimal status, which is much lower than in Rocconi et al.’s study (about 40%). Moreover, most of the patients who did not achieve optimal debulking status after primary CRS in our study had a residual tumor size $<$ 2 cm, and some of them also received bevacizumab treatment, resulting in the insignificance of this variable both in univariate and multivariate analyses. Lee et al. [27] retrospectively reviewed 223 patients diagnosed with stage IIC–IV serous EOC who were treated with more than six cycles of taxane-platinum first-line chemotherapy after primary CRS. The results showed that both serum CA125 level normalization after the first cycle of chemotherapy and a time to normalization by the third cycle were the most significant prognostic factors for both PFS and OS. However, they focused only on a specific population with serous cell type ovarian cancer. Although serous cell ovarian cancer accounts for most cases of EOC [2], the study population does not represent the general population of patients with EOC. Furthermore, the pattern of CA125 normalization in other histologic types of EOC could also serve as a valid indicator of PFS and OS, and reflect the degree of inherent chemosensitivity [13, 29, 30]. In addition, the authors did not include CA125-related factors in the clinicopathological variables as a whole in univariate and multivariate survival analyses, since some of the significant factors may have been unexpectedly diluted by the others. In another study conducted by Markman et al. [9], the authors reported that a CA125 level $\leqslant$ 10 u/mL after the sixth cycle of primary adjuvant chemotherapy may be an important prognostic factor, especially in those receiving further consolidation chemotherapy. These results are in agreement with those by Kim et al. [28], and both studies concluded that a CA125 level $\leqslant$ 10 u/mL after the sixth cycle of chemotherapy can help clinicians to define the patient population who may really benefit from a maintenance treatment strategy. In our study, a CA125 level $\leqslant$ 10 u/mL was significant in univariate but not in multivariate analysis. This may be because maintenance treatment was not offered to our patients. Although 25.5% of our patients received more than six cycles of chemotherapy, most of them received seven or eight cycles which is far from the definition of maintenance treatment.

Based on earlier studies, although CA125 normalization patterns could provide prognostic information to identify patients at risk of platinum resistance and poor prognosis, the exact timing of CA125 measurements was not clearly described. Some reports have demonstrated that CA125 normalization by the third cycle of chemotherapy is a good prognosticator [24, 27], whereas other studies have reported after the third cycle [25]. Given that the timing of subsequent chemotherapy may be postponed due to poor compliance, unfavorable performance status, or treatment toxicity, the actual time interval between every adjuvant chemotherapy cycle may vary in different patients. These factors could lead to a large discrepancy in the time between CA125 measurement and the actual administration of chemotherapy in each cycle, which has not been well discussed in previous studies. The major difference between our study and the previous studies mentioned above is that we calculated the time to CA125 normalization in days, which is an easier and more reliable way to determine the prognosis in real-world clinical practice. When we analyzed all of the CA125-related variables together, we found that CA125 normalization within 60 days was better than normalization by chemotherapy cycle in predicting survival.

Our study has several limitations. First, the retrospective nature of our study design and potential patient selection bias may have impacted the results. In addition, patients who received NACT followed by interval debulking surgery were excluded from our study, and this group of patients may have more extensive disease. We only included patients who received primary CRS, and most of them presented with FIGO stage III (88.7%) at diagnosis. These patients were considered to be eligible to receive primary CRS, had a higher likelihood of achieving optimal debulking surgery, and may have benefited from surgery based on previous prospective randomized trials showing that patients with FIGO stage IIIC with metastatic lesions $<$ 5 cm treated with primary CRS had better OS while those with stage IV disease may have benefited from receiving NACT [2, 31]. Second, the large amount of missing data regarding postoperative CA125 level meant that we could not analyze this variable; however, a postsurgical decrease in CA125 level was associated with improved OS in a previous study [30]. Third, our study excluded four patients who had a normal CA125 level before treatment. This reflects the limitation of using CA125 level in this population, since 7.6% of patients with advanced EOC may have a normal CA125 level ( $\leqslant$ 35 u/mL) at primary diagnosis [29], making it difficult to evaluate the therapeutic effect of treatment and predict the prognosis in this population based on our approach. In real-world experience, predicting early progression or recurrence is a complicated process due to the heterogeneous behavior of tumor cells, presenting with varying degrees of response to chemotherapy. Therefore, despite the significant finding in our study, the pattern of CA125 normalization may not serve as the best surrogate for outcomes of patients with a normal CA125 level before treatment.

5. Conclusion

In conclusion, this is the first study to measure the time to CA125 normalization in days rather than cycle number of adjuvant chemotherapy. CA125 normalization within 60 days can be considered as a checkpoint to evaluate survival outcomes in patients with advanced EOC and an elevated pretreatment CA125 level receiving primary CRS followed by adjuvant chemotherapy. If a patient is shown to have a poor prognosis based on this 60-day checkpoint, a higher potential of platinum-resistant disease should be considered, and early adjustments of the therapeutic plan, chemotherapy regimen, and follow-up interval may be necessary to improve outcomes. This concept can help physicians to provide more precise counseling to patients regarding their risk of persistent disease, recurrence, and the possible benefits of changing chemotherapy regimen and further maintenance therapy. Further prospective studies are required to optimize clinically significant cut-off values for the time to normalization of CA125 level for both OS and PFS endpoints.

Author contributions

Conception: L.H.

Interpretation or analysis of data: L.Y.C., L.H., F.H.C.

Preparation of the manuscript: L.Y.C.

Revision for important intellectual content: L.H., O.Y.C., W.C.H., F.H.C., T.C.C.

Supervision: L.H.

Supplementary data

The supplementary files are available to download from http://dx.doi.org/10.3233/CBM-210156.

Footnotes

Acknowledgments

We thank the Biostatistics Center of Kaohsiung Chang Gung Memorial Hospital for assistance with the statistical analysis.

References

Bast

R.C.

Klug

T.L.

John

E.S.

Jenison

Niloff

J.M.

Lazarus

Berkowitz

R.S.

Leavitt

Griffiths

C.T.

Parker

Zurawski

V.R.

and Knapp

R.C.

, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med 309 (1983), 883–887.

Lheureux

Gourley

Vergote

and Oza

A.M.

, Epithelial ovarian cancer, The Lancet 393 (2019), 1240–1253.

Ron

I.-G.

Inbar

Gelernter

Lewysohn

Ayalon

Dale

and Chaitchik

, Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma, Acta Obstet Gynecol Scand 73 (1994), 658–662.

Tuxen

M.K.

Soletormos

and Dombernowsky

, Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy, Br J Cancer 84 (2001), 1301–1307.

Gadducci

Cosio

Fanucchi

Negri

Cristofani

and Genazzani

A.R.

, The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma, Gynecol Oncol 93 (2004), 131–136.

Markman

Federico

Liu

P.Y.

Hannigan

and Alberts

, Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer, Gynecol Oncol 103 (2006), 195–198.

Juretzka

M.M.

Barakat

R.R.

Chi

D.S.

Iasonos

Dupont

Abu-Rustum

N.R.

Poynor

E.A.

Aghajanian

Spriggs

Hensley

M.L.

and Sabbatini

, CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy, Gynecol Oncol 104 (2007), 176–180.

Timmermans

Zwakman

Sonke

G.S.

Van de Vijver

K.K.

Duk

M.J.

van der Aa

M.A.

and Kruitwagen

R.F.

, Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer, Eur J Obstet Gynecol Reprod Biol 240 (2019), 364–369.

Markman

Liu

P.Y.

Rothenberg

M.L.

Monk

B.J.

Brady

and Alberts

D.S.

, Pretreatment CA-125 and risk of relapse in advanced ovarian cancer, J Clin Oncol 24 (2006), 1454–1458.

10.

Chatterjee

Hurley

L.C.

Levin

N.K.

Stack

and Tainsky

M.A.

, Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer, Cancer Biomarkers 20 (2017), 369–387.

11.

Guo

and Peng

, Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study, J Ovarian Res 10 (2017), 14.

12.

Vergote

I.B.

Børmer

O.P.

and Abeler

V.M.

, Evaluation of serum CA 125 levels in the monitoring of ovarian cancer, Am J Obstet Gynecol 157 (1987), 88–92.

13.

Tian

Markman

Zaino

Ozols

R.F.

McGuire

W.P.

Muggia

F.M.

Rose

P.G.

Spriggs

and Armstrong

D.K.

, CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study, Cancer 115 (2009), 1395–1403.

14.

Reid

B.M.

Permuth

J.B.

and Sellers

T.A.

, Epidemiology of ovarian cancer: a review, Cancer Biol Med 14 (2017), 9–32.

15.

Griffiths

C.T.

and Fuller

A.F.

, Intensive surgical and chemotherapeutic management of advanced ovarian cancer, Surg Clin North Am 58 (1978), 131–142.

16.

Schwartz

P.E.

Rutherford

T.J.

Chambers

J.T.

Kohorn

E.I.

and Thiel

R.P.

, Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival, Gynecol Oncol 72 (1999), 93–99.

17.

Vergote

Tropé

C.G.

Amant

Kristensen

G.B.

Ehlen

Johnson

Verheijen

R.H.M.

van der Burg

M.E.L.

Lacave

A.J.

Panici

P.B.

Kenter

G.G.

Casado

Mendiola

Coens

Verleye

Stuart

G.C.E.

Pecorelli

and Reed

N.S.

, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N Engl J Med 363 (2010), 943–953.

18.

Kehoe

Hook

Nankivell

Jayson

G.C.

Kitchener

Lopes

Luesley

Perren

Bannoo

Mascarenhas

Dobbs

Essapen

Twigg

Herod

McCluggage

Parmar

and Swart

A.-M.

, Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, The Lancet 386 (2015), 249–257.

19.

Crawford

S.M.

and Peace

, Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 16 (2005), 47–50.

20.

Prat

Parera

Peralta

Perez-Benavente

M.A.

Garcia

Gil-Moreno

Martinez-Palones

J.M.

Roxana

Baselga

and Del Campo

J.M.

, Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer, Ann Oncol 19 (2008), 327–331.

21.

Lin

Y.-H.

C.-H.

H.-C.

Chen

Y.-J.

Chen

Y.-Y.

Y.-C.

and Lin

, Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer, Cancer Biomarkers 28 (2020), 285–292.

22.

Usón

P.L.S.

Bugano

D.D.G.

França

M.S.

Antunes

Y.P.P.V.

Taranto

Kaliks

R.A.

and Del Giglio

, Does time-to-chemotherapy impact the outcomes of resected ovarian cancer? Meta-analysis of randomized and observational data, Int J Gynecol Cancer 27 (2017), 274.

23.

Meyer

and Rustin

G.J.

, Role of tumour markers in monitoring epithelial ovarian cancer, Br J Cancer 82 (2000), 1535–1538.

24.

Rocconi

R.P.

Matthews

K.S.

Kemper

M.K.

Hoskins

K.E.

Huh

W.K.

and Straughn

J.M.

, Jr., The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer, Gynecol Oncol 114 (2009), 242–245.

25.

Yang

Z.-J.

Zhao

B.-B.

and Li

, The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer, J Ovarian Res 9 (2016), 57–57.

26.

Skaznik-Wikiel

M.E.

Sukumvanich

Beriwal

Zorn

K.K.

Kelley

J.L.

Richard

S.D.

and Krivak

T.C.

, Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report, Int J Gynecol Cancer 21 (2011), 1013–1017.

27.

Lee

Chang

M.Y.

Yoo

Lee

K.E.

Chay

D.B.

Cho

Kim

Y.T.

and Kim

J.H.

, Clinical significance of CA125 level after the first cycle of chemotherapy on survival of patients with advanced ovarian cancer, Yonsei Med J 57 (2016), 580–587.

28.

Kim

H.S.

Park

N.H.

Chung

H.H.

Kim

J.W.

Song

Y.S.

and Kang

S.B.

, Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders’ survival in patients with advanced epithelial ovarian cancer, Onkologie 31 (2008), 315–320.

29.

Bai

Sha

Xiao

Gao

Cao

Yang

Chen

Wang

Zhang

and Shen

, The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study, Oncotarget 7 (2016), 15566–15576.

30.

Zwakman

van de Laar

Van Gorp

Zusterzeel

P.L.

Snijders

M.P.

Ferreira

Massuger

L.F.

and Kruitwagen

R.F.

, Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer, J Gynecol Oncol 28 (2017), e7.

31.

Vergote

Coens

Nankivell

Kristensen

G.B.

Parmar

M.K.B.

Ehlen

Jayson

G.C.

Johnson

Swart

A.M.

Verheijen

McCluggage

W.G.

Perren

Panici

P.B.

Kenter

Casado

Mendiola

Stuart

Reed

N.S.

Kehoe

Tropé G

Dobbs

Essapen

Hoskins

Green

Gilby

Van Baal

Twigg

Van Der Burg

M.E.L.

Godfrey

Lacave

A.J.

Angioli

Nath

Chin

Redman

Lotocki

Olaitan

Mosgaard

Rustin

Ind

Persic

Hogg

Van Der Velden

Ledermann

Peter Sykes

P.S.

Madhavan

Kannisto

Hird

Evans

Sandvei R

Gauthier

Cruickshank

D.J.

Ottevanger

P.B.

Pearson

Kitchener

Hall

Bessette

Pecorelli

Gerdin

Lopes

Fish

Barlow

Van Eygen

Floquet

Tholander

Gul

Gornall

Luesley

Kirwan

Symonds

Henry

Poole

McNeish

Hocking

Sammaraie

Speiser

Leblanc

Green

J.A.

De Oliveira

C.F.

Grimshaw

Zola

Parkin

Luesley

Lamb

Hong

Gillespie

Hamid

Ahmed

Plante

De Valk

Nordin

Clamp

Perez

Graham Dark

G.D.

Ferguson

MacGregor

Skailes

Jones

Gillespie

Cawdell

Leeson

Elit

Dittrich

Gotlieb

Poole

Cullimore

Crosse

Ridley

Head

Nieto

Awwad

Brinkmann

Eustace

Hindley

Katsaros

Popadiuk

Kristeller

Redman

Chan

Marth

Yiannakis

Lankaster

Beynon

Suhail

Indrajit

Hong

Quigley

Adeyemi

Persic

Lofts

McNally

Tristam

Lee

Counsell

Gleeson

Papadopoulos

Maggino

Honkoop

Ghatage

Vermorken

J.B.

De Greve

Boman

Petru

and Amant

, Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials, The Lancet Oncology 19 (2018), 1680–1687.

CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer

Abstract

BACKGROUND:

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS:

Keywords

1. Introduction

2. Materials and methods

2.1 Study population

2.2 Data collection and definition

3. Results

3.1 Patient characteristics

Table 1 Characteristics of the study population

3.3 Impact of CA125-related variables on survival

Table 2 Univariate Cox regression analysis of clinicopathological characteristics, and CA125-related prognostic factors for progression-free survival (PFS) and overall survival (OS)

5. Conclusion

Author contributions

Supplementary data

Footnotes

Acknowledgments

References

Table 1
Characteristics of the study population

Table 2
Univariate Cox regression analysis of clinicopathological characteristics, and CA125-related prognostic factors for progression-free survival (PFS) and overall survival (OS)